The YouTuber is buying Viking Therapeutics, a biopharmaceutical company with promising GLP-1 drugs in trials for weight loss and thyroid metabolic disorders. Despite being a speculative stock with no current revenue, its $7 billion market cap allows for significant growth. The company is managing its debt and expenses well, and analysts project a 79% upside, making it an attractive long-term play.
“I give them a 10 because they have a long Runway given the breadth of drugs that they have in the pipeline and for potential I give them a solid nine” — ▶ 16:20